Avalglucosidase alfa-ngpt_(Nexviazyme®)

Nexviazyme (avalglucosidase alfa‑ngpt) is covered only for the FDA‑approved indication of late‑onset Pompe disease in patients aged ≥1 year (other indications are not covered). Approval (up to 12 months) requires documented deficient acid α‑glucosidase activity or a pathogenic GAA gene mutation, prescribing by or consultation with a geneticist/neurologist/metabolic disorder or lysosomal storage disorder specialist, documentation of age, and dosing limited to ≤40 mg/kg IV no more often than every 2 weeks.

"Nexviazyme (avalglucosidase alfa-ngpt) is indicated for the treatment of individuals with late-onset Pompe disease (lysosomal acid α‑glucosidase deficiency)."

Sign up to see full coverage criteria, indications, and limitations.